Functional improvement with hylan G-F 20 in patients with knee osteoarthritis.
A systematic review of randomized, controlled, prospective clinical studies is described (8 trials; N = 1674 patients), with > 100 patients in each, which evaluated functional outcomes with hylan G-F 20 in secondary analyses. Hylan G-F 20 significantly improved Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) physical function versus appropriate/conventional care or corticosteroid, it significantly improved loss of activity versus saline, and it had similar functional improvements compared with progressive knee exercises or nonsteroidal anti-inflammatory drugs. Functional improvements with hylan G-F 20 also improved with pain relief. Hylan G-F 20 should be considered as part of a multimodal arthritis treatment regimen that focuses on improving function.
Brander
Victoria A
VA
Department of Physical Medicine and Rehabilitation, Northwestern University, Feinberg School of Medicine, 680 North Lakeshore Drive, Suite 1028, Chicago, IL 60611, USA. victoriabrander@aol.com
Stadler
Teresa S
TS
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004185:Disability Evaluation; D005081:Exercise Therapy; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007270:Injections, Intra-Articular; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology* / Q000628:therapy; D010146:Pain / Q000188:drug therapy / Q000503:physiopathology; D010147:Pain Measurement; D019152:Paracentesis; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001672:Biocompatible Materials; C049816:hylan; D006820:Hyaluronic Acid